Shanxi Zhendong Pharmaceutical Co Ltd
SZSE:300158
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shanxi Zhendong Pharmaceutical Co Ltd's latest stock split occurred on Jun 14, 2018
The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.
Before the split, Shanxi Zhendong Pharmaceutical Co Ltd traded at 12.05 per share. Afterward, the share price was about 4.2469.
The adjusted shares began trading on Jun 14, 2018. This was Shanxi Zhendong Pharmaceutical Co Ltd's 2nd stock split, following the previous one in Jul 23, 2012.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 29, 2026
|
|
Anhui Anfu Battery Technology Co Ltd
SSE:603031
|
29-for-20
x1.45
|
57.42 39.48 CNY | 41.08 41.08 CNY |
|
Apr 29, 2026
|
S
|
Shaanxi Meineng Clean Energy Corp Ltd
SZSE:001299
|
1-for-1
x1
|
15.61 11.5077 CNY | 11.39 11.39 CNY |
|
Apr 29, 2026
|
L
|
Leenos Corp
KOSDAQ:039980
|
1-for-5
/5
|
1481 7405 KRW | 9630 9630 KRW |
|
Apr 29, 2026
|
A
|
Alticast Corp
KOSDAQ:085810
|
1-for-5
/5
|
437 2185 KRW | 2465 2465 KRW |
|
Apr 29, 2026
|
P
|
Polaris Uno Inc
KOSDAQ:114630
|
1-for-5
/5
|
473 2365 KRW | 2465 2465 KRW |
603031
Shanxi Zhendong Pharmaceutical Co Ltd
Glance View
Shanxi Zhendong Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and distribution of Chinese traditional medicines and western medicines. The company is headquartered in Changzhi, Shanxi and currently employs 4,123 full-time employees. The company went IPO on 2011-01-07. The firm's main products include anti-tumor series, cardiovascular and cerebrovascular series, anti-infection series, digestive system series, vitamin nutrition series, respiratory system series, antipyretic analgesic series and nervous system series. The firm is also involved in the cultivation of medicinal herbs, as well as the wholesale and retail of pharmaceutical products. The firm distributes its products in domestic market, with North China market as its main market.
